Sandoz Group AG

Despite 16 biosimilars in the US, over 100 molecules await entry due to high development costs favoring big pharma. Recombinant proteins and monoclonal antibodies are potential biosimilar candidates, but lower market products face barriers. Regulatory agencies have eased guidelines for some drugs, yet comparative efficacy testing remains costly. Big pharma opposes changes, and biosimilar associations oppose the Inflation Reduction Act, which removes price negotiations if biosimilars are available. The author proposes reducing development costs by 70-80% and creating a biological Drug Master File for biosimilars to streamline development.

The EC approved Afqlir (aflibercept), a biosimilar to Eylea, for treating retinal diseases like nAMD. Sandoz's Chief Scientific Officer highlights the importance of accessible treatments for vision loss. Launch expected Q4 2025.

The 11th annual Clinical Trials in Oncology Europe 2024 conference in Munich will feature talks on AI strategy, patient imaging, and biotech company building, with speakers from Sandoz, Blue Earth Therapeutics, and Nvidia.

Sandoz receives European Commission approval for Afqlir® (aflibercept), a biosimilar to Eylea®, for treating retinal diseases including neovascular age-related macular degeneration (nAMD). Afqlir® will be available as a 2 mg vial kit and pre-filled syringe for intravitreal injection, with launch expected in Q4 2025.

Sandoz announces EC approval for Afqlir®, a biosimilar to Eylea®, for treating retinal diseases including nAMD, aiming to prevent blindness. Launch expected Q4 2025.

Sandoz announces EC approval for Afqlir®, a biosimilar to Eylea®, for treating retinal diseases including nAMD, aiming to prevent blindness. Launch expected Q4 2025, reinforcing Sandoz's commitment to accessible, high-quality biosimilars.

The EC approved Afqlir, a biosimilar to Eylea for treating retinal diseases like nAMD, with a launch expected in Q4 2025. Sandoz's Chief Scientific Officer highlights the importance of accessible, effective treatments for vision loss.

The global halal empty capsules market is projected to grow from USD 1.28 billion in 2024 to USD 2.16 billion by 2034, driven by increasing demand for halal-certified products and plant-based capsules. North America dominated the market in 2023, while Asia Pacific is expected to grow fastest. The gelatin segment led in 2023, but non-gelatin is projected to grow significantly. The pharmaceutical industry is the largest application segment, with the nutraceutical segment expected to grow rapidly. AI is enhancing drug manufacturing processes, and rising demand for dietary supplements and generic drugs is boosting market growth. Challenges include the lack of halal-certified raw materials and the costly certification process.